Metronomic capecitabine as adjuvant therapy provides compelling evidence in locoregionally advanced nasopharyngeal carcinoma

 A study conducted at the Sun Yet-sen University Cancer Center in Guangzhou, China, and recently presented at the 2021 ASCO Annual Meeting (June 4-8, 2021), indicated that "patients with loco regionally advanced nasopharyngeal carcinoma (NPC) experienced improved failure-free survival (FFS) and other survival outcomes with metronomic capecitabine."  Study results showed that metronomic capecitabine was not as toxic as other adjuvant therapies and thereby "significantly improved failure-free survival compared with observation."

To read more about this study, click here.  

Sources mentioned: 

Chen Y-P, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. The Lancet, Published online 7 June 2021. https://doi.org/10.1016/S0140-6736(21)01123-5

Kerbel RS, Andre N. Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. The Lancet, Published online 7 June 2021. https://doi.org/10.1016/S0140-6736(21)01240-X 

Ma J, Chen Y-P, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial. J Clin Oncol 2021;39(suppl 15; abstr 6003). DOI: 10.1200/JCO.2021.39.15_suppl.6003